CHARACTERIZATION OF HUMAN PAPILLOMAVIRUS VACCINES: THE WORLD EXPERIENCE
- 作者: Gorenkov D.1, Nikitina T.1, Volgin A.1, Klimov V.1
-
隶属关系:
- The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
- 期: 卷 22, 编号 4 (2019)
- 页面: 1454-1456
- 栏目: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/1028-7221/article/view/119514
- DOI: https://doi.org/10.31857/S102872210007055-5
- ID: 119514
如何引用文章
全文:
详细
Persistence of high-risk human papillomavirus (HPV) genotypes is the leading cause of cervical cancer, as well as anogenital and oropharyngeal cancers. This article focuses on analysis of the global use of the licensed HPV vaccines, given the introduction of HPV vaccination into national immunization programs of many countries. All vaccines are safe, immunogenic and effective in population usage, with the most frequent adverse event being injection-site reactions.
作者简介
D. Gorenkov
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
编辑信件的主要联系方式.
Email: fake@neicon.ru
Category 1 Expert,
Moscow
俄罗斯联邦T. Nikitina
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, Main Expert,
Moscow
俄罗斯联邦A. Volgin
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, Deputy Director of Centre for Evaluation and Control of MIBPs,
Moscow
俄罗斯联邦V. Klimov
The Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian Federation
Email: fake@neicon.ru
PhD, Deputy Director of Centre for Planning and Coordination of Scientific Activities,
Moscow
俄罗斯联邦
参考
- Ferlay J., Ervik M., Lam F., Colombet M., Mery L., Piсeros M., Znaor A., Soerjomataram I., Bray F. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: IARC. https://gco.iarc.fr/today
- Lin S. W., Ghosh A., Porras C., Markt S. C., Rodriguez A. C., Schiff man M., Wacholder S., Kemp T. J., Pinto L. A., Gonzalez P., Wentzensen N., Esser M. T., Matys K., Meuree A., Quint W., van Doorn L. J., Herrero R., Hildesheim A., Safaeian M. HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays. PLoS One. 2013;8(1): e53067. https://doi.org/10.1371/journal.pone.0053067
- Brotherton J. M. L, Bloem P. N., Population-based HPV vaccination programmes are safe and eff ective: 2017 update and the impetus for…, Best Practice & Research Clinical Obstetrics and Gynaecology (2017), http://dx.doi.org/10.1016/j.bpobgyn.2017.08.010
- Chaturvedi A. K., Graubard B. I., Broutian T., Pickard R. K. L, Tong Z. Y., Xiao W., Kahle L., Gillison M. L. Eff ect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States. J Clin Oncol. 2018;36(3):262. Epub 2017 Nov 28.
- Phillips A., Patel C., Pillsbury A. et al. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018;41:329. https://doi.org/10.1007/s40264-017-0625-z
